Cabozantinib Shows Promising Results in Treatment of Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma

At ASCO GU 2025, Dr. Sylvie Negrier presented the CABRAMET trial, a phase 2 study on cabozantinib in patients with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC). The trial showed promising efficacy, with a 61% response rate and 56% progression-free rate in brain metastases. Adverse events were consistent with known cabozantinib effects. The study also emphasized the importance of routine screenings for patients with brain metastases to better tailor therapeutic strategies.